NCT05702853View on ClinicalTrials.gov

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

November 6, 2026

Study Completion Date

December 30, 2026

Conditions
B-cell Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Interventions
DRUG

Cyclophosphamide injection

500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3

DRUG

Fludarabine Injection

30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3

BIOLOGICAL

CD19-CD34t metabolically programmed CAR transduced T-cells

Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping

Trial Locations (1)

29425

RECRUITING

Hollings Cancer Center at Medical University of South Carolina, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER